February 7, 2020 07:33 AM EST
FDA+

End­ing four years of le­gal fight, ARCH-backed syn­thet­ic DNA mak­er set­tles law­suit with CEO's for­mer em­ploy­er

Amber Tong

When Twist Bio­science filed for an IPO in 2018, one is­sue fea­tured promi­nent­ly in the sec­tions where ex­ecs warned in­vestors …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Lil­ly fi­nances new $500M biotech fund man­aged by a16z

Pfiz­er touts blad­der can­cer re­sults as first ad­vance­ment for some pa­tients 'in decades'

Ab­b­Vie writes off $3.5B on Cerev­el drug af­ter Phase 2 fail­ures

A service from the Financial Times